Michal Zapotocky1,2, Kiran Beera3, Jenny Adamski1,4, Normand Laperierre5, Sharon Guger6, Laura Janzen3,6, Alvaro Lassaletta1,7, Liana Figueiredo Nobre1, Ute Bartels1, Uri Tabori1, Cynthia Hawkins8, Stacey Urbach9, Derek S Tsang5, Peter B Dirks10,11, Michael D Taylor10,11, Eric Bouffet1, Donald J Mabbott3,12, Vijay Ramaswamy1,11. 1. Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada. 2. Department of Paediatric Haematology and Oncology, Second Medical School, Charles University and University Hospital Motol, Prague, Czech Republic. 3. Programme in Neuroscience and Mental Health, Hospital for Sick Children, Toronto, Ontario, Canada. 4. Department of Pediatric Oncology, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom. 5. Department of Radiation Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada. 6. Department of Psychology, Hospital for Sick Children, Toronto, Ontario, Canada. 7. Department of Paediatric Hematology and Oncology, Child Jesus Hospital, Madrid, Spain. 8. Department of Paediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada. 9. Division of Endocrinology, Hospital for Sick Children, Toronto, Ontario, Canada. 10. Division of Neurosurgery, Hospital for Sick Children, Toronto, Ontario, Canada. 11. Programme in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada. 12. Department of Psychology, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Posterior fossa ependymoma (PFE) comprises 2 groups, PF group A (PFA) and PF group B (PFB), with stark differences in outcome. However, to the authors' knowledge, the long-term outcomes of PFA ependymoma have not been described fully. The objective of the current study was to identify predictors of survival and neurocognitive outcome in a large consecutive cohort of subgrouped patients with PFE over 30 years. METHODS: Demographic, survival, and neurocognitive data were collected from consecutive patients diagnosed with PFE from 1985 through 2014 at the Hospital for Sick Children in Toronto, Ontario, Canada. Subgroup was assigned using genome-wide methylation array and/or immunoreactivity to histone H3 K27 trimethylation (H3K27me3). RESULTS: A total of 72 PFE cases were identified, 89% of which were PFA. There were no disease recurrences noted among patients with PFB. The 10-year progression-free survival rate for all patients with PFA was poor at 37.1% (95% confidence interval, 25.9%-53.1%). Analysis of consecutive 10-year epochs revealed significant improvements in progression-free survival and/or overall survival over time. This pertains to the increase in the rate of gross (macroscopic) total resection from 35% to 77% and the use of upfront radiotherapy increasing from 65% to 96% over the observed period and confirmed in a multivariable model. Using a mixed linear model, analysis of longitudinal neuropsychological outcomes restricted to patients with PFA who were treated with focal irradiation demonstrated significant continuous declines in the full-scale intelligence quotient over time with upfront conformal radiotherapy, even when correcting for hydrocephalus, number of surgeries, and age at diagnosis (-1.33 ± 0.42 points/year; P = .0042). CONCLUSIONS: Data from a molecularly informed large cohort of patients with PFE clearly indicate improved survival over time, related to more aggressive surgery and upfront radiotherapy. However, to the best of the authors' knowledge, the current study is the first, in a subgrouped cohort, to demonstrate that this approach results in reduced neurocognitive outcomes over time.
BACKGROUND: Posterior fossa ependymoma (PFE) comprises 2 groups, PF group A (PFA) and PF group B (PFB), with stark differences in outcome. However, to the authors' knowledge, the long-term outcomes of PFA ependymoma have not been described fully. The objective of the current study was to identify predictors of survival and neurocognitive outcome in a large consecutive cohort of subgrouped patients with PFE over 30 years. METHODS: Demographic, survival, and neurocognitive data were collected from consecutive patients diagnosed with PFE from 1985 through 2014 at the Hospital for Sick Children in Toronto, Ontario, Canada. Subgroup was assigned using genome-wide methylation array and/or immunoreactivity to histone H3 K27 trimethylation (H3K27me3). RESULTS: A total of 72 PFE cases were identified, 89% of which were PFA. There were no disease recurrences noted among patients with PFB. The 10-year progression-free survival rate for all patients with PFA was poor at 37.1% (95% confidence interval, 25.9%-53.1%). Analysis of consecutive 10-year epochs revealed significant improvements in progression-free survival and/or overall survival over time. This pertains to the increase in the rate of gross (macroscopic) total resection from 35% to 77% and the use of upfront radiotherapy increasing from 65% to 96% over the observed period and confirmed in a multivariable model. Using a mixed linear model, analysis of longitudinal neuropsychological outcomes restricted to patients with PFA who were treated with focal irradiation demonstrated significant continuous declines in the full-scale intelligence quotient over time with upfront conformal radiotherapy, even when correcting for hydrocephalus, number of surgeries, and age at diagnosis (-1.33 ± 0.42 points/year; P = .0042). CONCLUSIONS: Data from a molecularly informed large cohort of patients with PFE clearly indicate improved survival over time, related to more aggressive surgery and upfront radiotherapy. However, to the best of the authors' knowledge, the current study is the first, in a subgrouped cohort, to demonstrate that this approach results in reduced neurocognitive outcomes over time.
Authors: Douglas R Strother; Lucie Lafay-Cousin; James M Boyett; Peter Burger; Patricia Aronin; Louis Constine; Patricia Duffner; Mehmet Kocak; Larry E Kun; Marc E Horowitz; Amar Gajjar Journal: Neuro Oncol Date: 2013-12-12 Impact factor: 12.300
Authors: Heather M Conklin; Robert J Ogg; Jason M Ashford; Matthew A Scoggins; Ping Zou; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Sima Jeha; Lu Huang; Hui Zhang Journal: J Clin Oncol Date: 2015-10-12 Impact factor: 44.544
Authors: Thomas E Merchant; Susan R Rose; Christina Bosley; Shengjie Wu; Xiaoping Xiong; Robert H Lustig Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544
Authors: Kristian W Pajtler; Ji Wen; Martin Sill; Tong Lin; Wilda Orisme; Bo Tang; Jens-Martin Hübner; Vijay Ramaswamy; Sujuan Jia; James D Dalton; Kelly Haupfear; Hazel A Rogers; Chandanamali Punchihewa; Ryan Lee; John Easton; Gang Wu; Timothy A Ritzmann; Rebecca Chapman; Lukas Chavez; Fredrick A Boop; Paul Klimo; Noah D Sabin; Robert Ogg; Stephen C Mack; Brian D Freibaum; Hong Joo Kim; Hendrik Witt; David T W Jones; Baohan Vo; Amar Gajjar; Stan Pounds; Arzu Onar-Thomas; Martine F Roussel; Jinghui Zhang; J Paul Taylor; Thomas E Merchant; Richard Grundy; Ruth G Tatevossian; Michael D Taylor; Stefan M Pfister; Andrey Korshunov; Marcel Kool; David W Ellison Journal: Acta Neuropathol Date: 2018-06-16 Impact factor: 17.088
Authors: R G Grundy; S H Wilne; K J Robinson; J W Ironside; T Cox; W K Chong; A Michalski; R H A Campbell; C C Bailey; N Thorp; B Pizer; J Punt; D A Walker; D W Ellison; D Machin Journal: Eur J Cancer Date: 2010-01 Impact factor: 9.162
Authors: Florence M G Cavalli; Jens-Martin Hübner; Tanvi Sharma; Betty Luu; Martin Sill; Michal Zapotocky; Stephen C Mack; Hendrik Witt; Tong Lin; David J H Shih; Ben Ho; Mariarita Santi; Lyndsey Emery; Juliette Hukin; Christopher Dunham; Roger E McLendon; Eric S Lipp; Sridharan Gururangan; Andrew Grossbach; Pim French; Johan M Kros; Marie-Lise C van Veelen; Amulya A Nageswara Rao; Caterina Giannini; Sarah Leary; Shin Jung; Claudia C Faria; Jaume Mora; Ulrich Schüller; Marta M Alonso; Jennifer A Chan; Almos Klekner; Lola B Chambless; Eugene I Hwang; Maura Massimino; Charles G Eberhart; Matthias A Karajannis; Benjamin Lu; Linda M Liau; Massimo Zollo; Veronica Ferrucci; Carlos Carlotti; Daniela P C Tirapelli; Uri Tabori; Eric Bouffet; Marina Ryzhova; David W Ellison; Thomas E Merchant; Mark R Gilbert; Terri S Armstrong; Andrey Korshunov; Stefan M Pfister; Michael D Taylor; Kenneth Aldape; Kristian W Pajtler; Marcel Kool; Vijay Ramaswamy Journal: Acta Neuropathol Date: 2018-07-17 Impact factor: 17.088
Authors: Santhosh A Upadhyaya; Giles W Robinson; Arzu Onar-Thomas; Brent A Orr; Catherine A Billups; Daniel C Bowers; Anne E Bendel; Tim Hassall; John R Crawford; Sonia Partap; Paul G Fisher; Ruth G Tatevossian; Tiffany Seah; Ibrahim A Qaddoumi; Anna Vinitsky; Gregory T Armstrong; Noah D Sabin; Christopher L Tinkle; Paul Klimo; Danny J Indelicato; Frederick A Boop; Thomas E Merchant; David W Ellison; Amar Gajjar Journal: Neuro Oncol Date: 2019-10-09 Impact factor: 12.300
Authors: Craig Horbinski; Keith L Ligon; Priscilla Brastianos; Jason T Huse; Monica Venere; Susan Chang; Jan Buckner; Timothy Cloughesy; Robert B Jenkins; Caterina Giannini; Roger Stupp; L Burt Nabors; Patrick Y Wen; Kenneth J Aldape; Rimas V Lukas; Evanthia Galanis; Charles G Eberhart; Daniel J Brat; Jann N Sarkaria Journal: Neuro Oncol Date: 2019-12-17 Impact factor: 12.300
Authors: J Kjær Grønbæk; S Toescu; R Frič; P Nilsson; C Castor; C Mallucci; B Pizer; K Aquilina; E Molinari; M Aasved Hjort; A Karppinen; G Rutkauskiene; K Mudra; B Markia; K van Baarsen; E Hoving; J Zipfel; M Wibroe; K Nysom; K Schmiegelow; A Sehested; R Mathiasen; M Juhler Journal: Childs Nerv Syst Date: 2022-02-14 Impact factor: 1.475
Authors: Vladimír Beneš; Michal Zápotocký; Petr Libý; Jakub Táborský; Jana Blažková; Jana Blažková; David Sumerauer; Adéla Mišove; Ivana Perníková; Martin Kynčl; Lenka Krsková; Miroslav Koblížek; Josef Zámečník; Ondřej Bradáč; Michal Tichý Journal: Acta Neurochir (Wien) Date: 2022-01-19 Impact factor: 2.216
Authors: Ade Oyefiade; Iris Paltin; Cinzia R De Luca; Kristina K Hardy; David R Grosshans; Murali Chintagumpala; Donald J Mabbott; Lisa S Kahalley Journal: J Clin Oncol Date: 2021-04-22 Impact factor: 50.717
Authors: Lorena V Baroni; Lakshmikirupa Sundaresan; Ayala Heled; Hallie Coltin; Kristian W Pajtler; Tong Lin; Thomas E Merchant; Roger McLendon; Claudia Faria; Molly Buntine; Christine L White; Stefan M Pfister; Mark R Gilbert; Terri S Armstrong; Eric Bouffet; Sachin Kumar; Michael D Taylor; Kenneth D Aldape; David W Ellison; Nicholas G Gottardo; Marcel Kool; Andrey Korshunov; Jordan R Hansford; Vijay Ramaswamy Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 13.029